Climb Bio, Inc. (CLYM)
10.19
-0.35
(-3.32%)
USD |
NASDAQ |
Oct 23, 16:00
10.34
+0.15
(+1.47%)
After-Hours: 20:00
Climb Bio Enterprise Value : 403.47M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 403.47M |
| October 22, 2026 | 423.57M |
| October 21, 2026 | 442.52M |
| October 20, 2026 | 438.50M |
| October 19, 2026 | 377.05M |
| October 16, 2026 | 382.22M |
| October 15, 2026 | 444.82M |
| October 14, 2026 | 409.21M |
| October 13, 2026 | 410.36M |
| October 12, 2026 | 440.23M |
| October 09, 2026 | 449.99M |
| October 08, 2026 | 441.95M |
| October 07, 2026 | 433.33M |
| October 06, 2026 | 431.61M |
| October 05, 2026 | 452.86M |
| October 02, 2026 | 446.54M |
| October 01, 2026 | 454.01M |
| September 30, 2026 | 476.99M |
| September 29, 2026 | 478.71M |
| September 28, 2026 | 492.49M |
| September 25, 2026 | 487.90M |
| September 24, 2026 | 501.11M |
| September 23, 2026 | 537.29M |
| September 22, 2026 | 634.36M |
| September 21, 2026 | 601.62M |
| Date | Value |
|---|---|
| September 18, 2026 | 625.17M |
| September 17, 2026 | 625.75M |
| September 16, 2026 | 628.62M |
| September 15, 2026 | 617.13M |
| September 14, 2026 | 654.46M |
| September 11, 2026 | 636.66M |
| September 10, 2026 | 676.86M |
| September 09, 2026 | 682.61M |
| September 08, 2026 | 731.43M |
| September 04, 2026 | 709.60M |
| September 03, 2026 | 656.19M |
| September 02, 2026 | 682.61M |
| September 01, 2026 | 669.40M |
| August 31, 2026 | 606.79M |
| August 28, 2026 | 655.04M |
| August 27, 2026 | 683.18M |
| August 26, 2026 | 741.77M |
| August 25, 2026 | 842.85M |
| August 24, 2026 | 760.15M |
| August 21, 2026 | 810.69M |
| August 20, 2026 | 795.76M |
| August 19, 2026 | 814.14M |
| August 18, 2026 | 817.01M |
| August 17, 2026 | 819.88M |
| August 14, 2026 | 756.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Korsana Biosciences, Inc. | 17.65M |
| Cullinan Therapeutics, Inc. | 595.12M |
| Q32 Bio, Inc. | 104.35M |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.50M |
| Total Expenses (Quarterly) | 13.50M |
| EPS Diluted (Quarterly) | -0.1772 |
| Earnings Yield | -8.12% |
| Normalized Earnings Yield | -8.125 |